Norges Bank’s Bicara Therapeutics BCAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-42,889
Closed -$722K – 1772
2025
Q4
$722K Hold
42,889
– – ﹤0.01% 1539
2025
Q3
$677K Hold
42,889
– – ﹤0.01% 1462
2025
Q2
$398K Hold
42,889
– – ﹤0.01% 1646
2025
Q1
$559K Sell
42,889
-27,111
-39% -$360K ﹤0.01% 1681
2024
Q4
$1.22M Hold
70,000
– – ﹤0.01% 1742
2024
Q3
$1.78M Buy
+70,000
New +$1.79M ﹤0.01% 1669

Other funds holding BCAX

Norges Bank's BCAX Position: Q2 2026 in Review

Norges Bank sold out of Bicara Therapeutics (BCAX) in Q2 2026, closing a stake of 42,889 shares — an estimated $722K sold.

Norges Bank first reported a position in BCAX in Q3 2024 and held it in 6 quarters. The position peaked at $1.78M in Q3 2024. 171 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Norges Bank reported no remaining Bicara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Norges Bank sold 42,889 Bicara Therapeutics shares in Q2 2026, an estimated $722K.
  • Norges Bank first reported a position in Bicara Therapeutics in Q3 2024 and held it in 6 quarters.
  • Norges Bank's Bicara Therapeutics position peaked at $1.78M in Q3 2024.
  • 171 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Norges Bank's 13F filing for Q2 2026, filed 12 Aug 2026.